Mechanisms of Resistance for CAR T Therapy – OncLive
OncLive |
Mechanisms of Resistance for CAR T Therapy
OncLive And so, when we’ve had patients who relapsed and still retained the CD19 antigen and they’ve generally had a loss of CAR T cells, they, in general, do not respond to a second infusion. And in those who don’t respond, we’ve been able to show that they … |
|
UK’s CGT Catapult Partners with Freeline to Build Gene Therapy Manufacturing Platform
Genetic Engineering & Biotechnology News The Cell and Gene Therapy (CGT) Catapult said today it will partner with Freeline Therapeutics to build the gene therapy developer’s proprietary manufacturing platform at the CGT Catapult’s large-scale GMP manufacturing center in Stevenage … |
OncLive |
Treating Advanced Bladder Cancer in the Future
OncLive Daniel J. George, MD: Immunotherapy in bladder cancer is here to stay. There is no doubt about the fact that we have changed this platinum-refractory setting. There’s no doubt in my mind that this is going to become more and more a part of our … |
Genetic Engineering & Biotechnology News |
The Challenge of Immunotherapy: Staying on Target
Genetic Engineering & Biotechnology News Some of the side effects of immunotherapy resemble symptoms of autoimmune diseases; he added that experts treating Crohn’s disease might be able to help oncologists treat colitis in cancer patients, for instance. Immune checkpoint blockade works by … |
OncLive |
MSI Testing’s Impact on Immunotherapy in Gastric Cancers
OncLive And our data from MSKCC in the metastatic setting, which was recently published in Cancer Discovery, shows that MSI metastatic gastric cancer progresses on systemic chemotherapy within the first 4 months of treatment, showing that these tumors are … |
Pharmaceutical Business Review |
Novartis sBLA for CAR–T Therapy Kymriah Accepted by FDA
Nasdaq A novel immunocellular therapy and one-time treatment, Kymriah uses patient’s T cells to fight cancer. CAR-T is manufactured for individual patients using their own cells thereby making it different from typical small molecule or biologic therapies … Novartis gets US priority review for Kymriah for adults with lymphomaReuters Novartis’ Kymriah nabs speedy reviews in US, Europe for lymphoma treatmentPharmaceutical Business Review US FDA grants priority review status to Novartis’ sBLA for Kymriah to treat adults with r/r DLBCLpharmabiz.com |
Life Sciences Intellectual Property Review |
CRISPR: the gene editing tool making the world go round
Lexology The battle over clustered regularly interspaced short palindromic repeat (CRISPR) technology between Feng Zhang and the Broad Institute at the Massachusetts Institute of Technology on the one side and Jennifer Doudna, Emmanuelle Charpentier, Krzysztof … Mixed views on Broad’s fate after EPO revokes CRISPR patentLife Sciences Intellectual Property Review |
Pacific Standard |
Why Gene Therapy Is No Longer a Pipe Dream
Pacific Standard Last year will be remembered for many things, many of them not good. But here’s at least one flicker of hope: 2017 may go down as the year gene therapy finally turned a corner. In late December, the Food and Drug Administration announced its approval … FDA Approves Spark Therapeutics’ Gene Therapy for Inherited Vision LossTheafricom |